CD19 and neoplasm: The most influential topics were the utilization of CARTs in hematological malignancies, the issues on CRS, CD19, and the anti-tumor activity and efficacy of CARTs, while among the latest hotspots were, if we exclude studying CARTs in solid cancers, universal CARTs, CAR-NKs, CD22, and anakinra (the IL1 receptor antagonist).